Phillip M. Pierorazio, MD
Urology
Accepting new patients
Sees patients age 18 and up
Penn Urology University City
View 2 additional locations
Make an appointmentCall 215-662-8699
Penn Medicine Provider

About me

  • Chief, Section of Urology, Penn Presbyterian Medical Center
  • Professor of Surgery at the Hospital of the University of Pennsylvania

I am a board-certified urologist with training and expertise in urologic cancers.  I have expertise in all malignancies of the urinary tract, but my clinical and academic practice focuses on kidney cancer (renal cell carcinoma), testicular cancer (germ cell tumors), upper tract urothelial cancer, and prostate cancer.  I offer patients both open and minimally invasive surgeries including laparoscopic and robotic surgeries of the kidney, bladder, prostate, and retroperitoneal lymph node dissection for testicular cancer.  I am a firm believer that surgery is a last option and prefer non-operative management whenever possible – but routinely perform surgeries for complex cancers and patients. 

My research team includes basic science researchers, statisticians, and other urologists both inside and outside Penn Medicine.  We focus on cancer biomarkers, improving outcomes for complex surgeries, evaluating the quality of care through a cancer journey, and minimizing the impact of surgical treatments.  I run the Delayed Intervention and Surveillance for Small Renal Masses (DISSRM) Registry - one of the largest active surveillance registries for patients with small kidney tumors. I am involved in a number of national guideline panels, including both the American Urological Association (AUA) and National Comprehensive Cancer Network (NCCN) Guidelines Committees, for Kidney, Testicular and Upper Tract Urothelial Cancer. 

While I experience tremendous satisfaction from generating research and guidelines that influence the care of cancer patients around the world, in my opinion, there is no greater impact in medicine than taking a patient through a cancer journey.  My greatest joy comes from the relationships we build through diagnosis, treatment, and the survivorship journey.

Education and training

  • Medical School: Columbia University
  • Residency: Johns Hopkins Hospital

What my patients think about me

Average Rating

565 reviews

Comments are submitted by patients and reflect their views and opinions. The comments are not endorsed by and do not necessarily reflect the views of Penn Medicine.

October 2025
very kind.
October 2025
he's good at what he does.
October 2025
he is an excellent provider
October 2025
have already recommended him

Insurance accepted

My Locations

Penn Medicine hospital privileges

  • Hospital of the University of Pennsylvania: Has privileges to treat patients in the hospital.
  • Pennsylvania Hospital: Has privileges to treat patients in the hospital.
  • Penn Presbyterian Medical Center: Has privileges to treat patients in the hospital.
Dr. Pierorazio is a Penn Medicine physician. In New Jersey, providers are affiliated with Penn Medicine through Clinical Health Care Associates of New Jersey or Princeton Healthcare Affiliated Physicians, PC.

Qualifications and experience

Treatments and Conditions

My research

Blackmur JP, van der Mijn JCK, Warren AY, Browning L, Burgers F, Hirsch MS, Kapur P, Mehra R, Rao P, Signoretti S, Bex A, Stewart GD, van Montfoort ML, Jones JO; International Neoadjuvant Kidney Cancer Consortium. Assessing pathological response to neoadjuvant therapy in renal cell carcinoma: a systematic review and guidelines for sampling and reporting standards from the International Neoadjuvant Kidney Cancer Consortium. , Lancet Oncol. 2025 Oct;26(10):e536-e546. doi: 10.1016/S1470-2045(25)00345-6. PMID: 41038202 Review.: 2025

Alkhatib KY, Cheaib JG, Pallauf M, Alam R, Patel HD, Wlajnitz T, Singla N, Chang P, Wagner AA, Pavlovich CP, McKiernan JM, Guzzo TJ, Allaf ME, Pierorazio PM. Active Surveillance versus Primary Intervention for Clinical T1a Kidney Tumors: Twelve-Year Experience of the DISSRM Prospective Comparative Study. , J Urol. 2025 Apr 22:101097JU0000000000004583. doi: 10.1097/JU.0000000000004583. Online ahead of print.PMID: 40262276: 2025

Gilligan T, Lin DW, Adra N, Bagrodia A, Feldman DR, Yamoah K, Aggarwal R, Chandrasekar T, Costa D, Drakaki A, Eggener S, Emamekhoo H, Geynisman DM, Graham L, Humphrey P, Leuva H, Levine EG, Luckenbaugh A, Maughan BL, McGregor B, Monk P, Picus J, Pierorazio P, Rais-Bahrami S, Reichert Z, Rwigema JC, Saylor P, Shah A, Shah S, Singla N, Sircar K, VanderWeele D, Zhumkhawala A, Montgomery S, Sliker B. NCCN Guidelines® Insights: Testicular Cancer, Version 2.2025. , J Natl Compr Canc Netw. 2025 Apr;23(4):e250018. doi: 10.6004/jnccn.2025.0018. PMID: 40203876: 2025

Hu B, Alsyouf M, Farkouh A, Cary C, Masterson T, Einhorn L, Adra N, Boorjian SA, Kollmannsberger C, Schuckman A, So A, Black PC, Bagrodia A, Skinner E, Alemozaffar M, Brand T, Eggener S, Pierorazio P, Stratton K, Nappi L, Nichols C, Daneshmand S. Accuracy of 18F-Fluorodeoxyglucose Positron Emission Tomography in Early Metastatic Testicular Seminoma: Analysis From the SEMS Trial. , J Urol. 2025 Apr 9:101097JU0000000000004561. doi: 10.1097/JU.0000000000004561. Online ahead of print. PMID: 40203124: 2025

Cortese BD, Alkhatib KY, Harmatz IM, Michel KF, Lee DJ, Guzzo TJ, Vaughn DJ, Moses KA, Pierorazio PM, Talwar R. . The impact of telemedicine on racial and ethnic disparities in oncologic care during the COVID-19 pandemic , Am J Cancer Res. 2025 Mar 15;15(3):1224-1233. doi: 10.62347/RNJS4301. eCollection 2025. PMID: 40226475 Free PMC article.: 2025

Lattanzio K, Alkhatib K, Guzzo T, Lee DJ, Pierorazio P, Bivalacqua T, Schurhamer B. . Case study: Pulsed electric field ablation for salvage prostate cancer ablation , Urol Case Rep. 2025 Mar 25;60:103023. doi: 10.1016/j.eucr.2025.103023. eCollection 2025 May.PMID: 40270519 Free PMC article.: 2025

Pallauf M, Rezaee M, Elias R, Wlajnitz T, Fletcher SA, Cheaib J, Alkhatib K, Chang P, Wagner AA, McKiernan JM, Allaf ME, Pierorazio PM, Singla N. Tumour size is associated with growth rates of >0.5 cm/year and delayed intervention in small renal masses in patients on active surveillance. , BJU Int. 2025 Jan 28. doi: 10.1111/bju.16651. Online ahead of print. PMID: 39873312: 2025

Alkhatib KY, Cheaib JG, Pallauf M, Alam R, Patel HD, Wlajnitz T, Singla N, Chang P, Wagner AA, Pavlovich CP, McKiernan JM, Guzzo TJ, Allaf ME, Pierorazio PM. Active Surveillance versus Primary Intervention for Clinical T1a Kidney Tumors: Twelve-Year Experience of the DISSRM Prospective Comparative Study. , J Urol. 2025 Apr 22:101097JU0000000000004583. doi: 10.1097/JU.0000000000004583. Online ahead of print.PMID: 40262276: 2025

Raver M, Ahmed M, Okhawere KE, Saini I, Chaturvedi R, Patel M, Sauer Calvo R, Soputro NA, Ramos R, Billah M, Crivellaro S, Mansour AM, Kaouk J, Singla N, Porter J, Abaza R, Bhandari A, Hemal AK, Pierorazio PM, Chung BI, Rogers CG, Mehrazin R, Badani K, Stifelman M. Adoption of Single-Port Robotic Partial Nephrectomy Increases Utilization of the Retroperitoneal Approach: A Report from the Single-Port Advanced Research Consortium. , J Laparoendosc Adv Surg Tech A. 2025 Feb;35(2):131-137. doi: 10.1089/lap.2024.0305. Epub 2025 Feb 6. PMID: 39909473: 2025

Briggs LG, Psutka SP, Van Ligten MJ, Beck KL, Sinha D, Gill VS, Alkhatib KY, Durant AM, Bain PA, Quillen J, Dodoo C, Pierorazio PM, Abdul-Muhsin H, Tyson MD, Trinh QD, Parke SC. Exercise, diet and psychological support for patients with testicular cancer. , Nat Rev Urol. 2025 Sep 22. doi: 10.1038/s41585-025-01089-5. Online ahead of print. PMID: 40983774 Review.: 2025

View all publications